INNOVIVE Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting

NEW YORK--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB: IVPH) today announced that interim data from a Phase I trial of INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for GleevecĀ®-resistant or treatment-intolerant chronic myelogenous leukemia, will be presented at the 43rd American Society of Clinical Oncology Annual Meeting. The meeting takes place June 1- 5, 2007 at McCormick Place in Chicago, Illinois.

Back to news